Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr579.50 DKK
Change Today -2.00 / -0.34%
Volume 109.3K
As of 11:04 AM 07/3/15 All times are local (Market data is delayed by at least 15 minutes).

genmab a/s (GEN) Snapshot

Open
kr582.50
Previous Close
kr581.50
Day High
kr585.00
Day Low
kr577.00
52 Week High
06/11/15 - kr632.00
52 Week Low
07/18/14 - kr204.80
Market Cap
34.0B
Average Volume 10 Days
260.8K
EPS TTM
kr7.31
Shares Outstanding
58.7M
EX-Date
--
P/E TM
79.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMAB A/S (GEN)

Related News

No related news articles were found.

genmab a/s (GEN) Related Businessweek News

No Related Businessweek News Found

genmab a/s (GEN) Details

Genmab A/S, a biotechnology company, develops human antibody therapeutics for the treatment of cancer in Denmark, the Netherlands, the United States, and internationally. The company markets Ofatumumab, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia. Its products under development include Ofatumumab that is in Phase III clinical studies to treat follicular lymphoma and pemphigus vulgaris; and Phase II clinical studies for the treatment of relapsing-remitting multiple sclerosis, as well as Daratumumab, a CD38 monoclonal antibody that is in Phase III clinical studies to treat multiple myeloma. The company’s products under development also comprises HuMax-TF-ADC, an antibody-drug conjugate (ADC), which is in Phase I clinical studies for the treatment of solid tumors; and Teprotumumab, a human antibody that is in Phase II clinical studies for active thyroid eye disease, as well as in Phase I clinical studies for diabetic macular edema. In addition, it has approximately 20 active pre-clinical pipeline programs, including naked antibodies, immune effector function enhanced antibodies, bispecific antibodies, and ADCs. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

175 Employees
Last Reported Date: 05/12/15
Founded in 1999

genmab a/s (GEN) Top Compensated Officers

Co-Founder, Chief Executive Officer and Presi...
Total Annual Compensation: kr11.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.2M
Compensation as of Fiscal Year 2014.

genmab a/s (GEN) Key Developments

Genmab A/s Announces Gilead Submits Supplemental New Drug Application with the U.S. Food and Drug Administration

Genmab A/S announced that Gilead has published that it has submitted a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration to include data from a phase 3 study of Zydelig (idelalisib) in combination with ofatumumab in previously-treated patients with chronic lymphocytic leukemia (CLL). As reported the study included 261 patients and the results showed a 73% reduction in the risk of disease progression or death for patients in the Zydelig plus ofatumumab arm versus the ofatumumab arm alone. The safety profile of Zydelig was similar to prior studies in previously-treated patients with CLL. Grade 3 adverse events occurring in the Zydelig plus ofatumumab arm included diarrhea/colitis (20.2%), pneumonia (12.7%) and febrile neutropenia (11.6%). The data was presented over the weekend at the American Society of Clinical Oncology Meeting 2015 held in Chicago, USA. Gilead also announced it plans to submit a supplemental filing to the European Medicines Agency later this year.

Genmab A/S Announces Earnings Results for the First Quarter Ended March 31, 2015; Updates Earnings Guidance for the Year 2015

Genmab A/S announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced net income of DKK 217.29 million or DKK 3.64 per diluted share compared to DKK 98.5 million or DKK 1.76 per diluted share for the same quarter ended March 31, 2014. Net income before tax was DKK 217.3 million compared to DKK 99.8 million for the same quarter ended March 31, 2014. For the year 2015, the company has updated its revenue guidance range to be between DKK 650 million and DKK 725 million. The company has updated its operating income guidance range to be between DKK 200 million and DKK 275 million.

BioNTech AG Signs Co-Development and Commercialization Agreement with Genmab

BioNTech AG announced that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody® technology platform. The aim of the collaboration is to develop and commercialize immunomodulatory antibodies that activate the immune system against cancer. Under the terms of the agreement, BioNTech will provide proprietary immunomodulatory antibodies and onco-immunotherapy expertise to be combined with Genmab's innovative DuoBody® technology platform for the generation of bispecific antibodies. This joint approach is expected to yield superior bispecific antibodies which specifically stimulate the immune system against cancer. Genmab will pay an upfront fee of USD 10 million to BioNTech and additional potential near-term payments of up to USD 5 million if certain BioNTech assets are nominated for further development. The aim of the collaboration is to jointly generate and select one or more bispecific antibody product candidates for clinical development and commercialization by the two parties; development and commercialization costs together with product ownership will be shared equally.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:DC kr579.50 DKK -2.00

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €11.05 EUR -0.07
arGEN-X BV €10.23 EUR -0.02
MorphoSys AG €64.77 EUR +0.72
Seattle Genetics Inc $47.65 USD -0.17
XOMA Corp $3.73 USD -0.025
View Industry Companies
 

Industry Analysis

GEN

Industry Average

Valuation GEN Industry Range
Price/Earnings 83.4x
Price/Sales 48.5x
Price/Book 13.5x
Price/Cash Flow 84.1x
TEV/Sales 45.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMAB A/S, please visit www.genmab.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.